Toward In Vitro Epigenetic Drug Design for Thyroid Cancer: The Promise of PF-03814735, an Aurora Kinase Inhibitor

Sadeleştirilmiş öğe sayfası
dc.contributor.authorDalva\\-Aydemir, Sevim
dc.contributor.authorAkyerli, Cemaliye Boylu
dc.contributor.authorYuksel, Sirin Kilicturgay
dc.contributor.authorKeskin, Hilal
dc.contributor.authorYakicier, Mustafa Cengiz
dc.date.accessioned2025-10-16T15:22:50Z
dc.date.issued2019
dc.identifier.doi10.1089/omi.2019.0050
dc.identifier.otherWOS:000487406100001
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/7894
dc.publisherMARY ANN LIEBERT, INC
dc.sourceOMICS-A JOURNAL OF INTEGRATIVE BIOLOGY
dc.subjectepigenetics
dc.subjectdrug design
dc.subjectPF\\-03814735
dc.subjectAurora kinase inhibitor
dc.subjecttelomerase
dc.subjectthyroid cancer
dc.titleToward In Vitro Epigenetic Drug Design for Thyroid Cancer: The Promise of PF-03814735, an Aurora Kinase Inhibitor
dc.typeArticle

Dosyalar

Koleksiyonlar

WOS
Load more